跳至主要内容
临床试验/NCT03396978
NCT03396978终止不适用

The Influence of Gonadal Hormone Suppression on Adipocyte Lineage and the Microbiome

University of Colorado, Denver1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2018年1月11日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
入组人数
5
试验地点
1
主要终点
Accumulation of Myeloid Cells

研究概览

简要总结

This research study plans to learn more about the role of female sex hormones on adipose tissue (or fat) and the gut microbiome (or the organisms that are in your digestive tract). The rationale for this study is that the rate at which women gain fat (especially in the stomach region) increases after menopause. It is thought to be due to the loss of estrogen because post-menopausal women who take estrogen gain less weight than those who do not take estrogen. Gut bacteria process estrogen and help determine the types of estrogen that circulate in the body. These bacteria can be changed with lifestyle factors such as diet, and may therefore, also affect the risk of diseases that are more common in women after menopause i.e., cardiovascular disease and cancer. In this study the investigators will obtain fat biopsies before and after 6 months of ovarian hormone suppression to measure how the fat cells change with the loss of female sex hormones (e.g., medical menopause). The investigators will also obtain stool and urine samples before and every month during the study to measure changes in the microbiome.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者
是

入选标准

  • •Enrollment into the parent protocol (COMIRB 16-1479 - The impact of estrogen status on the biological function of brown adipose tissue in women measured using quantitative PET/CT; PI - Edward Melanson, PhD)
  • •Participation in GnRHag intervention

排除标准

  • •Known allergy to lidocaine or other numbing medication
  • •Uncontrolled bleeding disorder or inability to withhold aspirin/NSAIDs or other blood thinning medications for 7 days prior to biopsy procedure.

研究组 & 干预措施

GnRHag

Experimental

Participants will undergo 6 months of gonadotropin releasing hormone agonist (GnRHag) therapy (intramuscular injection of leuprolide acetate 3.75 mg for depot suspension; Lupron; TAP Pharmaceutical Products, Inc.; Lake Forest, IL) to chronically suppress ovarian hormones. A single injection of leuprolide acetate produces an initial stimulation (for up to 3 wk) followed by a prolonged suppression of pituitary gonadotropins and ovarian hormones. Repeated monthly dosing suppresses ovarian hormone secretion.

干预措施: GnRHag (Other)

结局指标

主要结局

Accumulation of Myeloid Cells

时间窗: 8 months after enrollment of last participant

Quantification of accumulation of myeloid cells in abdominal subcutaneous adipose tissue of women before and after gonadal hormone suppression as assessed by CD45+/CD14+ staining via flow cytometry of isolated adipose stroma.

Progenitor proliferation and adipogenic potential

时间窗: 1 year after completion of last participant

Progenitor proliferation measured by BrdU and adipogenic potential as measured by Oil Red-O staining with quantification by absorbance. Adipocyte specific gene/protein expression will be measured to confirm adipocyte status.

Gut microbial diversity

时间窗: 1 year after completion of last participant

Comparison of gut microbial diversity before and after gonadal hormone suppression at monthly intervals as assessed by sequencing of the V4 region of 16s rRNA

次要结局

  • In Vitro Metabolic Phenotyping(2 years after completion of last participant)
  • β-glucuronidase activity(2 years after completion of last participant)
  • Estrogen parent: metabolite ratios(2 years after completion of last participant)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验